Current anti-vascular endothelial growth factor dosing regimens: Benefits and burden

Ophthalmology

Volumn 120, Issue 5 SUPPL., 2013, Pages S3-

  Haller, Julia A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

ARTICLE; DRUG SAFETY; ECONOMIC ASPECT; EXUDATIVE MACULAR DEGENERATION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LIFESTYLE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84876971026     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.01.057     Document Type: Article

References (22)

1. S.A. Mousa, S.S. Mousa Current status of vascular endothelial growth factor inhibition in age-related macular degeneration BioDrugs 24 2010 183 194
2. U. Schmidt-Erfurth, B. Eldem, R. Guymer Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 2011 831 839
3. T.S. Chang, N.M. Bressler, J.T. Fine Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial Arch Ophthalmol 125 2007 1460 1469
4. D.M. Brown, P.K. Kaiser, M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
5. A. Oishi, M. Mandai, A. Nishida Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration Eur J Ophthalmol 21 2011 777 782
6. P. Abraham, H. Yue, L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 Am J Ophthalmol 150 2010 315 324 e311
7. C.D. Regillo, D.M. Brown, P. Abraham Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
8. D.M. Brown, C.D. Regillo Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients Am J Ophthalmol 144 2007 627 637
9. R. Spaide Ranibizumab according to need: a treatment for age-related macular degeneration Am J Ophthalmol 143 2007 679 680
10. R.A. Mittra, J.M. Jumper ASRS 2011 Preferences and Trends Membership Survey 2010 American Society of Retina Specialists Chicago
11. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58 e41
12. D.S. Boyer, J.S. Heier, D.M. Brown A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
13. F.G. Holz, W. Amoaku, J. Donate Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study Ophthalmology 118 2011 663 671
14. H. Dadgostar, A.A. Ventura, J.Y. Chung Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 2009 1740 1747
15. S.P. Rothenbuehler, D. Waeber, C.K. Brinkmann Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration Am J Ophthalmol 147 2009 831 837
16. S.Y. Cohen, L. Dubois, R. Tadayoni Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting Am J Ophthalmol 148 2009 409 413
17. O.P. Gupta, G. Shienbaum, A.H. Patel A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact Ophthalmology 117 2010 2134 2140
18. H. Oubraham, S.Y. Cohen, S. Samimi Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 2011 26 30
19. A. Tufail, P.J. Patel, C. Egan Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study BMJ 340 2010 c2459
20. D.F. Martin, M.G. Maguire, S.L. Fine Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
21. CATT Research Group D.F. Martin, M.G. Maguire et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
22. G. Shienbaum, O.P. Gupta, C. Fecarotta Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact Am J Ophthalmol 153 2012 468 473.e1